Načítá se...
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities
Lenalidomide is an immunomodulatory drug (IMiD) with activity in lymphoid malignancies occurring primarily through immune modulation (eg, T-cell immune synapse enhancement and NK-cell/T-cell effector augmentation) and antiproliferative effects. Food and Drug Administration–approved for bortezomib-re...
Uloženo v:
| Vydáno v: | Blood |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Hematology
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4467884/ https://ncbi.nlm.nih.gov/pubmed/25736312 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-11-567792 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|